Celltrion’s COVID-19 Treatment Regdanvimab Is Approved In Korea
Follows Conditional Approval In February From Korean Regulator
Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.
